Inactive Instrument

IntelGenx Technologies Corp. Share Price OTC Bulletin Board

Equities

IGX

US45822R1014

Pharmaceuticals

End-of-day quote OTC Bulletin Board
- CAD - Intraday chart for IntelGenx Technologies Corp.

Financials

Sales 2022 10L 12.98L 7.92Cr Sales 2023 10.39L 14.2L 8.67Cr Capitalization 2.41Cr 3.3Cr 201.22Cr
Net income 2022 -1Cr -1.37Cr -83Cr Net income 2023 -90L -1.23Cr -75Cr EV / Sales 2022 44.7 x
Net Debt 2022 79.84L 1.09Cr 67Cr Net Debt 2023 1.32Cr 1.81Cr 110.26Cr EV / Sales 2023 35.9 x
P/E ratio 2022
-2.82 x
P/E ratio 2023
-2.43 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 77.6%
More Fundamentals * Assessed data
IntelGenx Reports Launch of Sale and Investment Solicitation Process MT
IntelGenx Brief: Says Obtained Court-Approval of a Sale and Investment Solicitation Process; Had Recently Initiated Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives MT
ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp.. CI
IntelGenx Begins Restructuring Proceedings Under CCAA to Implement Review of Strategic Alternatives MT
IntelGenx Brief: Initiating Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives MT
IntelGenx Technologies Corp. Announces Board Resignations CI
IntelGenx Technologies Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives CI
IntelGenx Technologies Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial CI
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA MT
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA CI
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises MT
Transcript : IntelGenx Technologies Corp., Q4 2023 Earnings Call, Mar 21, 2024
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences MT
More news
Managers TitleAgeSince
Chief Executive Officer 66 13/23/13
Director of Finance/CFO 61 20/15/20
Chairman 77 01/06/01
Members of the board TitleAgeSince
Chairman 77 01/06/01
Director/Board Member 54 09/16/09
Director/Board Member 72 08/09/08
More insiders
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. It provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others.
More about the company